Log in | Register

Effect of the use of low and high potency statins and sepsis outcomes

Shu-Yu Ou| Hsi Chu| Pei-Wen Chao| Shuo-Ming Ou| Yi-Jung Lee| Shu-Chen Kuo| Szu-Yuan Li| Chia-Jen Shih| Yung-Tai Chen
Original
Volume 40, Issue 10 / October , 2014

Pages 1509 - 1517

Abstract

Introduction

Although statins have been shown to have cholesterol-lowering effects, their pleiotropic benefits on sepsis remain a matter of debate. In addition, the influence of statin potency on sepsis-related mortality has never been explored. The aim of our study was to determine the sepsis outcomes of low- and high-potency statin users and non-users.

Methods

This nationwide, population-based, propensity score-matched analysis used data from the linked administrative databases of Taiwan’s National Health Insurance program. Patients were hospitalized for sepsis between 2000 and 2010. All-cause mortality and major adverse consequences of sepsis, such as in-hospital death, intensive care unit admission, shock events, and the use of mechanical ventilation, were assessed. Patients were divided into high-potency statin users (at least 10 mg rosuvastatin, at least 20 mg atorvastatin, or at least 40 mg simvastatin), low-potency statin users (all other statin treatments), and non-users.

Results

A propensity score-matched cohort of 27,792 statin users and 27,792 non-users was included. Of 27,792 statin users, 9,785 (35.2 %) were treated with high-potency statins and 18,007 (64.8 %) were treated with low-potency statins. The 1-year mortality risk was significantly lower among both low-potency [adjusted hazard ratio (aHR) 0.89, 95 % confidence interval (CI) 0.85–0.93] and high-potency (aHR 0.80, 95 % CI 0.75–0.86) statin users compared with non-users. The risks of mortality and adverse consequences of sepsis were lower among high-potency than among low-potency statin users.

Conclusions

High-potency statin use is associated with a lower risk of sepsis-related mortality compared with low-potency statin use.

Keywords

References

  1. Ballantyne CM, Raichlen JS, Cain VA (2008) Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (measuring effective reductions in cholesterol using rosuvastatin) trial. J Am Coll Cardiol 52:626–632
    • View reference on PubMed
    • View reference on publisher's website
  2. Maron DJ, Fazio S, Linton MF (2000) Current perspectives on statins. Circulation 101:207–213
    • View reference on PubMed
    • View reference on publisher's website
  3. John S, Schneider MP, Delles C, Jacobi J, Schmieder RE (2005) Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients. Am Heart J 149:473
    • View reference on PubMed
    • View reference on publisher's website
  4. Lahera V, Goicoechea M, de Vinuesa SG, Miana M, De las Heras N, Cachofeiro V, Luno J (2007) Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: beneficial effects of statins. Curr Med Chem 14:243–248
    • View reference on PubMed
    • View reference on publisher's website
  5. Skaletz-Rorowski A, Walsh K (2003) Statin therapy and angiogenesis. Curr Opin Lipidol 14:599–603
    • View reference on PubMed
    • View reference on publisher's website
  6. Son JW, Koh KK, Ahn JY, Jin DK, Park GS, Kim DS, Shin EK (2003) Effects of statin on plaque stability and thrombogenicity in hypercholesterolemic patients with coronary artery disease. Int J Cardiol 88:77–82
    • View reference on PubMed
    • View reference on publisher's website
  7. Wiersinga WJ, Leopold SJ, Cranendonk DR, van der Poll T (2013) Host innate immune responses to sepsis. Virulence 5(1):36–44
    • View reference on PubMed
    • View reference on publisher's website
  8. Tleyjeh IM, Kashour T, Hakim FA, Zimmerman VA, Erwin PJ, Sutton AJ, Ibrahim T (2009) Statins for the prevention and treatment of infections: a systematic review and meta-analysis. Arch Intern Med 169:1658–1667
    • View reference on PubMed
    • View reference on publisher's website
  9. Dobesh PP, Olsen KM (2014) Statins role in the prevention and treatment of sepsis. Pharmacol Res doi:10.1016/j.phrs.2014.04.010
  10. Antonelli M, Bonten M, Chastre J, Citerio G, Conti G, Curtis JR, De Backer D, Hedenstierna G, Joannidis M, Macrae D, Mancebo J, Maggiore SM, Mebazaa A, Preiser JC, Rocco P, Timsit JF, Wernerman J, Zhang H (2012) Year in review in Intensive Care Medicine 2011. II. Cardiovascular, infections, pneumonia and sepsis, critical care organization and outcome, education, ultrasonography, metabolism and coagulation. Intensive Care Med 38:345–358
  11. Ando H, Takamura T, Ota T, Nagai Y, Kobayashi K (2000) Cerivastatin improves survival of mice with lipopolysaccharide-induced sepsis. J Pharmacol Exp Ther 294:1043–1046
    • View reference on PubMed
  12. Kopterides P, Falagas ME (2009) Statins for sepsis: a critical and updated review. Clin Microbiol Infect 15:325–334
    • View reference on PubMed
    • View reference on publisher's website
  13. Mortensen EM, Restrepo MI, Copeland LA, Pugh JA, Anzueto A, Cornell JE, Pugh MJ (2007) Impact of previous statin and angiotensin II receptor blocker use on mortality in patients hospitalized with sepsis. Pharmacotherapy 27:1619–1626
    • View reference on PubMed
    • View reference on publisher's website
  14. Kruger P, Bailey M, Bellomo R, Cooper DJ, Harward M, Higgins A, Howe B, Jones D, Joyce C, Kostner K, McNeil J, Nichol A, Roberts, Venkatesh B, Group AN-SI-ACT (2013) A multicenter randomized trial of atorvastatin therapy in intensive care patients with severe sepsis. Am J Respir Crit Care Med 187:743–750
    • View reference on PubMed
    • View reference on publisher's website
  15. Yang KC, Chien JY, Tseng WK, Hsueh PR, Yu CJ, Wu CC (2007) Statins do not improve short-term survival in an oriental population with sepsis. Am J Emerg Med 25:494–501
    • View reference on PubMed
    • View reference on publisher's website
  16. Fernandez R, De Pedro VJ, Artigas A (2006) Statin therapy prior to ICU admission: protection against infection or a severity marker? Intensive Care Med 32:160–164
  17. Leung S, Pokharel R, Gong MN (2012) Statins and outcomes in patients with bloodstream infection: a propensity-matched analysis. Crit Care Med 40:1064–1071
    • View reference on PubMed
    • View reference on publisher's website
  18. Patel JM, Thickett DR, Gao F, Sapey E (2013) Statins for sepsis: distinguishing signal from the noise when designing clinical trials. Am J Respir Crit Care Med 188:874
    • View reference on PubMed
    • View reference on publisher's website
  19. Hollis S, Campbell F (1999) What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ 319:670–674
    • View reference on PubMed
    • View reference on publisher's website
  20. Dormuth CR, Hemmelgarn BR, Paterson JM, James MT, Teare GF, Raymond CB, Lafrance JP, Levy A, Garg AX, Ernst P, Canadian Network for Observational Drug Effect Studies (2013) Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases. BMJ 346:f880
    • View reference on PubMed
    • View reference on publisher's website
  21. WHO Collaborating Center for Drugs Statistics Methodology (2003) ATC index with DDDs 2003. WHO, Oslo
  22. Chang WP, Liu ME, Chang WC, Yang AC, Ku YC, Pai JT, Huang HL, Tsai SJ (2013) Sleep apnea and the risk of dementia: a population-based 5-year follow-up study in Taiwan. PLoS One 8:e78655
    • View reference on PubMed
    • View reference on publisher's website
  23. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383
    • View reference on PubMed
    • View reference on publisher's website
  24. Rubin DB, Thomas N (1996) Matching using estimated propensity scores: relating theory to practice. Biometrics 52:249–264
    • View reference on PubMed
    • View reference on publisher's website
  25. Austin PC (2008) A critical appraisal of propensity-score matching in the medical literature between 1996 and 2003. Stat Med 27:2037–2049
    • View reference on PubMed
    • View reference on publisher's website
  26. Brealey DA, Singer M, Terblanche M (2011) Potential metabolic consequences of statins in sepsis. Crit Care Med 39:1514–1520
    • View reference on PubMed
    • View reference on publisher's website
  27. Antonelli M, Bonten M, Chastre J, Citerio G, Conti G, Curtis JR, De Backer D, Hedenstierna G, Joannidis M, Macrae D, Mancebo J, Maggiore SM, Mebazaa A, Preiser JC, Rocco P, Timsit JF, Wernerman J, Zhang H (2012) Year in review in Intensive Care Medicine 2011: I. nephrology, epidemiology, nutrition and therapeutics, neurology, ethical and legal issues, experimentals. Intensive Care Med 38:192–209
  28. Martin CP, Talbert RL, Burgess DS, Peters JI (2007) Effectiveness of statins in reducing the rate of severe sepsis: a retrospective evaluation. Pharmacotherapy 27:20–26
    • View reference on PubMed
    • View reference on publisher's website
  29. Dobesh PP, Klepser DG, McGuire TR, Morgan CW, Olsen KM (2009) Reduction in mortality associated with statin therapy in patients with severe sepsis. Pharmacotherapy 29:621–630
    • View reference on PubMed
    • View reference on publisher's website
  30. Papazian L, Roch A, Charles PE, Penot-Ragon C, Perrin G, Roulier P, Goutorbe P, Lefrant JY, Wiramus S, Jung B, Perbet S, Hernu R, Nau A, Baldesi O, Allardet-Servent J, Baumstarck K, Jouve E, Moussa M, Hraiech S, Guervilly C, Forel JM, Group S-VS (2013) Effect of statin therapy on mortality in patients with ventilator-associated pneumonia: a randomized clinical trial. JAMA 310:1692–1700
    • View reference on PubMed
    • View reference on publisher's website
  31. Antonelli M, Bonten M, Chastre J, Citerio G, Conti G, Curtis JR, De Backer D, Hedenstierna G, Joannidis M, Macrae D, Mancebo J, Maggiore SM, Mebazaa A, Preiser JC, Rocco P, Timsit JF, Wernerman J, Zhang H (2012) Year in review in Intensive Care Medicine 2011: III. ARDS and ECMO, weaning, mechanical ventilation, noninvasive ventilation, pediatrics and miscellanea. Intensive Care Med 38:542–556
  32. Burke JP (2003) Infection control—a problem for patient safety. N Engl J Med 348:651–656
    • View reference on PubMed
    • View reference on publisher's website
  33. Liu CY, Liao CH, Chen YC, Chang SC (2010) Changing epidemiology of nosocomial bloodstream infections in 11 teaching hospitals in Taiwan between 1993 and 2006. J Microbiol Immunol Infect 43:416–429
    • View reference on PubMed
    • View reference on publisher's website
  34. Almog Y, Shefer A, Novack V, Maimon N, Barski L, Eizinger M, Friger M, Zeller L, Danon A (2004) Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 110:880–885
    • View reference on PubMed
    • View reference on publisher's website
  35. Fuller BM, Gajera M, Schorr C, Gerber D, Dellinger RP, Zanotti S (2012) The association of prior statin use in septic shock treated with early goal directed therapy. Eur J Emerg Med 19:226–230
    • View reference on PubMed
    • View reference on publisher's website
  36. Minneci PC, Deans KJ, Banks SM, Eichacker PQ, Natanson C (2004) Meta-analysis: the effect of steroids on survival and shock during sepsis depends on the dose. Ann Intern Med 141:47–56
    • View reference on PubMed
    • View reference on publisher's website
  37. Kruger PS, Harward ML, Jones MA, Joyce CJ, Kostner KM, Roberts MS, Venkatesh B (2011) Continuation of statin therapy in patients with presumed infection: a randomized controlled trial. Am J Respir Crit Care Med 183:774–781
    • View reference on PubMed
    • View reference on publisher's website
  38. Bruyere R, Vigneron C, Prin S, Pechinot A, Quenot JP, Aho S, Papazian L, Charles PE (2014) Impact of prior statin therapy on the outcome of patients with suspected ventilator-associated pneumonia: an observational study. Crit Care 18:R83
    • View reference on PubMed
    • View reference on publisher's website
  39. Loppnow H, Zhang L, Buerke M, Lautenschlager M, Chen L, Frister A, Schlitt A, Luther T, Song N, Hofmann B, Rose-John S, Silber RE, Muller-Werdan U, Werdan K (2011) Statins potently reduce the cytokine-mediated IL-6 release in SMC/MNC cocultures. J Cell Mol Med 15:994–1004
    • View reference on PubMed
    • View reference on publisher's website
  40. Austin PC (2011) An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res 46:399–424
    • View reference on publisher's website

Sign In

Connect with ICM

Top 5 Articles Editors Picks Supplement